Whether the results are amazing, good or just so so.....none of it matters without cash.  Shenzhen Hepalink bought in and yet there still wasn't enough cash to design a sufficiently robust trial with enough power to get us across the Phase 3 finish line.

If there is another partner waiting in the wings...Will there be enough cash to properly finance a trial with a big enough margin for error so that Apabetalone doesn't suffer another near miss when a bigger trial would have succeeded? 

I think they have it, or at least that they will....and that this period of uncertainty is being used by those wishing to accumulate.  Of course that is simply opinion obviously, there is no free lunch and no such thing as a sure thing.  But imo the ONLY reason to even consider holding or buying RVX is if you believe a partnership or buyout is in the cards, otherwise this company is dead in the water as near as I can tell.